Previous studies have proposed neutralizing CXCR4 as a therapeutic approach for non-Hodgkin’s lymphoma [83, 84] and have elucidated CXCR4-mediated cell migration in KARPAS299 cells [85]. This evidence concerns the gene CXCR4 and non-Hodgkin lymphoma.